Dulaglutide is a GLP-1 receptor agonist. It is filed in this library under hormones & metabolism, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Dulaglutide has an FDA-approved product on the U.S. market, marketed as Trulicity under application BLA125469.
The current label is held by A-S Medication Solutions.
From the FDA label
® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.Quoted from the FDA-approved prescribing information
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions, and Nonclinical Toxicology ]. TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potentQuoted from the FDA-approved prescribing information
The evidence
One source on Dulaglutide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Dulaglutide's FDA-approved label indicates it for glycemic control or for a glucose emergency. These are the markers clinicians use when assessing blood sugar and insulin. They are listed here so you can read about them, not as a statement that Dulaglutide changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Dulaglutide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides